Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Rheumatology > Rheumatology > Flashcards

Rheumatology Flashcards

1
Q

Abatacept

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Alkylating Agents

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Anti-CCP or ACPA

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Auto-antibodies of scleroderma (systemic sclerosis)

  • Which (1) related to limited disease
  • Which (2) related to diffuse disease
  • Which (1) decreases the risk of severe lung disease
  • Which (1) increases the risk of ILD
  • Which (1) is associated with renal disease, skin involvement and malignancy
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Autoantibodies in SLE

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Autoantibodies in SLE
Most Sensitive
Most Specific
Implication of Dense Fine Speckled ANA

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Azathioprine
Cyclosporin
Leflunomide
Methotrexate

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Azathioprine and TMPT
Drugs not to combine with AZA

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Behcet’s disease

  • HLA association
  • Describe disease course and Rx
A

HLA-B51!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Belimumab - drug profile

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Best treatment for palindromic Rheumatism

A

Palindromic rheumatism (PR) is a syndrome characterised by recurrent, self-resolving inflammatory attacks in and around the joints, consists of arthritis or periarticular soft tissue inflammation. Course is often acute onset, with sudden and rapidly developing attacks or flares. There is pain, redness, swelling, and disability of one or multiple joints. The interval between recurrent palindromic attacks and the length of an attack is extremely variable from few hours to days. Attacks may become more frequent with time but there is no joint damage after attacks. It is thought to be an autoimmune disease, possibly an abortive form of rheumatoid arthritis.

Hydroxychloroquine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Causes of Visual Loss in GCA

  • ?most common
  • and which vessel is involved
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Comparison of the various forms of Spondyloarthritis

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Contraindications to anti-TNFa therapy (5)

A

Malignancy within the past 5 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Contraindications to pregnancy in SLE (7)

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Cytokine Modulators in RA

  • abatacept
  • anakinra
  • baricitinib
  • rituximab
  • tocilizumab
  • tofacitinib
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Definition of Inflammatory Back Pain:

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Diagnosis of Sjogren’s Syndrome

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Diagnosis of Sjogren’s Syndrome

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Diagnostic Criteria for SLE

A

Definitions

  • Discoid rash - red rash raisedm disk-shaped patches
  • serositis - inflamamtion of linign around the lungs
  • Kidney disoder - persistent proteinuria or celular casts in the urine
  • Neurologic disorder - seizures or psychosis
  • Blood disorder - anaemia, leukopenia, lymphopenia or thrombocytopenia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Difference between limited and generalised GPA (Wegner’s)

A

The absence/presence of renal involvement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

DMARDs and pregnancy

A

csDMARDs during pregnancy

  1. Minimal foetal and maternal risk
    • hydroxychlorquinine, sulfalazine and azathioprine
  2. May be used selectively
    • corticosteroids, ored does nto cross the placenta, try to limit to 10mg per day - risk of gestational diabetes, small for gestational age babies, preterm delivery
    • NSAIDs, safest during 2nd trimester, avoid during 3rd trimester due to risk of premature closure of ductus arteriosus
  3. Moderate to high risk of foetal harm
    • Methotrexate
    • Leflunomide
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Epidemiology and Causes of Polyarteritis Nodosa

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Epidemiology and Pathogenesis of Takayasu arteritis

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Epidemiology and Presentation of Ank. Spond

A

Most common spondylitis - 1% of the population

  • males > females 3:1
  • main determinant = frequency of HLA B27 in population approx 5%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Epidemiology of Scleroderma (Systemic Sclerosis)

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Features Favouring MCTD over SLE other primary autoimmunes

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Felty’s syndrome HLA association

A

HLA DRW4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

General Management of SLE (5)

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Hydroxychloroquine

  • which SLE patient’s should be prescribed
  • Benefits (7)
  • Main concerning SE and RF for this
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Hypersensitivity Vasculitis

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Impact on SLE on:
Fertility
Pregnancy
Flares

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Implications of anti-Ro and anti-La antibodies in SLE and pregnancy

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Implications of anti-Ro and anti-La antibodies in SLE and pregnancy

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Implications of APLS antibiodies in SLE and pregnancy

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Implications of Primary Sjogren’s Syndrome

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Indications for Renal Bx in SLE

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Indicators of Poor Prognosis in RA (6)

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Induction and Maintence Therapies for lupus nephritis

A

Class III, IV +/- V

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Interpretation of Synovial Fluid

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Is plasma exchange of benefit in ANCA associated pauci-immune glomerulonephritis? What do the trials show for management of ANCA associated vasculitis according to disease severity?

A

Yes MEPEX trial

  • better renal recovery but no change in mortality
  • should be used in those with severe renal involvement (Cr >500)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Key driver of pathology in CPP arthropathy

A

NLRP3 -> activates IL-1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

Limited vs Diffuse Systemic Sclerosis

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Management of Fibromyalgia

A

Education is key!

Medications:

  • TCAs
  • Gabapentinoids
  • SNRIs
  • Tramadol
  • Low-dose naltrexone
  • Propranolol

Management – interventions best AVOIDED

  • Opioids
  • Paracetamol
  • NSAIDs
  • Glucocorticoids
  • Benzodiazepines
  • Most CAM therapies
  • Cannabinoids?
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

Management of Raynaud’s Disease

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

Measures of Disease Activity in SLE (5)

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

Most common cardiovascular manifestation of SLE

A

Pericarditis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

Most common cause of drug induced ANCA+ vasculitis

A

Hydralazine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

Most sensitive autoantibody for drug induced lupus

A

Anti Histone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

Most significant complication of SLE in pregnancy

A

CHB for baby! :(

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

Mucocutaneous Lupus

  • Types
  • which are photosensitive
  • which needs to be treated aggressively?
A
52
Q

Other autoantibodies of RA (3)

A
53
Q

Other features of Psoriatic Arthritis

A
54
Q

Polyarteritis Nodosa

  • Is it ANCA positive or negative?
  • Common or rare
  • Most common secondary cause
  • Presentation + most common organ
  • Treatment
A
55
Q

Polyarteritis Nodosa Presentation

A
56
Q

Poor prognostic markers in RA

A
57
Q

Predictors of Severe Lung Disease in Scleroderma (5)

A
58
Q

Preferred immunosuppressive agent for Rx of ILD and skin disease in scleroderma

A

Skin

  • Mycophenlate is likely the treatment of choice for severe skin disease. May spontaneously remit
59
Q

Presentation of Acute Calcium Pyrophosphate crystal pathologies

A

Clinical presentation

Acute CPP crystal arthritis:

  • Typically monoarthritis; knee most common; wrist, shoulder, ankle, elbow.
  • Acute inflammatory arthritis.
  • Self-limited: 1-3 weeks duration.

Chronic CPP crystal inflammatory arthritis:

  • Can mimic seronegative rheumatoid arthritis, polymyalgia rheumatica.

Osteoarthritis with CPPD:

  • Causes OA in joints not typically involved (MCP joints, wrists, elbows).

Synovial fluid analysis:

  • Synovial fluid leukocytosis, >90% neutrophils
  • Rhomboid or rod-shaped crystals.
  • Compensated polarised light microscopy: minority (20%) show weak positive birefringence
  • Harder to identify than MSU crystals.

Plain radiographs:

  • Involvement at sites uncommon for primary osteoarthritis (MCP joints, wrists, elbows, shoulders).
60
Q

Proportion of patient’s with psoriasis who have PsA

A

30%

61
Q

Psoriatic Arthritis

  • Most common pattern
  • HLA association
  • Other skin manifestations
  • Rx
  • Important association
A
62
Q

Psoriatic Arthritis

  • Onset of skin vs joint
  • Patterns (5)
A
63
Q

Psoriatic Arthritis - treatment

A
  • NSAIDs –Symptom relief
  • csDMARDs– Methotrexate, Sulfasalazine, Leflunomide
    • Surprisingly little data; efficacy of MTX controversial –20mg weekly effective
  • Anti-TNF –Adalimumab, Certolizumab pegol, Etanercept, Golimumab, Infliximab
  • Anti-IL17 –Secukinumab, Ixekizumab
  • Anti-p40 subunit IL12/23 –Ustekinumab; anti-p19 subunit IL-23 -guselkumab
64
Q

RA and pregnancy

A
65
Q

RA and surgery

  • which drug to consider increasing
  • which drug to consider withholding
A
66
Q

Radiographic hallmarks of RA (6)

A
67
Q

Radiological findings of joint disease

A
68
Q

Recommended treatment for induction and maintence for Wegner’s (GPA)

A

Oral cyclophosphamide for induction for 3 months
Then PO azathioprine or MTx for maintenance
Azathioprine > mycophenolate

69
Q

Rheumatoid Arthritis

  • Important pro-inflammatory cytokines (2)
  • HLA association (1)
  • Describe the hand involvement
  • What % have extra-articular disease?
  • What % are seronegative?
  • Which drug is the backbone of therapy?
  • Which is the best biologic DMARD
A
70
Q

Risk Factors and Pathogenesis of SLE

A
71
Q

Risk Factors for Calcium Pyrophosphate Arthritis

A
72
Q

Risk Factors for Rapid Progression in Ank. Spond

A
73
Q

Risk Factors for Renal Crisis in Scleroderma (5)

A
74
Q

Scleroderma Renal Crisis

  • presentation
  • treatment
A

ACEi, ACEi, ACEi! CAPTOPRIL

  • Untreated, can progress to end stage renal disease over 1-2 months
  • Mainstay of treatment is effective and prompt blood pressure control
    • improves/stabilizes renal function in up to 70% and improves 1 year survival up to 80%
75
Q

Secukinumab

A
76
Q

Should Rituximab be used in ANCA vasculitis

A

No.
Increased risk of relapse at 18 months

77
Q

Spondylosis vs DISH (Diffuse Idiopathic Skeletal Hyperostosis) vs Ank Spond

A
78
Q

Structure of RhF
-2 associations

A

IgM antibodies directed against IgG

79
Q

Summary of IBD associated Spondyloarthritis

A
  • Estimates vary - approx 10-20% of IBD patients
  • More common in those with:
    • other extra-intetsinal features
    • complications of bowel disease
    • large bowel invovlement (for Crohn’s)
  • Two subtypes
    • axial - asymptomatic sacro-ilitis in up to 20%
    • peripheral
  • peripheral arthritis
    • usually acute, oligoarticular and lower limb
    • deformities/erosions rare
    • can be self-limiting, related to flares of IBD
    • Rarel, progressive independent of IBD activity
    • Can see other features of SpA eg. ethesitis
  • Axial disease
    • Same clinical presentation as AS

Treatment

  • NSAIDs - use with caution
  • DMARDs - sulfalazine, joints and bowel
    • Not effective in axial disease
  • Controlling bowel disease often helps
    • surgery in Crohns not usually helpful
  • Anti-TNF for joints and bowel
  • Axial disease treat as per AS
80
Q

Summary of Reactive Arthritis

  • timing
  • infections
  • Rx
  • natural Hx
A
81
Q

Systemic Complications of Primary Sjogren’s Syndrome

A
82
Q

TNFalpha antagonists

A
83
Q

Treatment of GCA

A
84
Q

Treatment of Lupus Nephritis

  • Name each of the 6 classes
  • Name which require immunosuppression
  • what are the 4 adjunctive therapies?
A

TREATMENT

  • Induction = glucocorticoids + cyclo OR MMF
    Maintenance = MMF or AZA
85
Q

Treatment of Polyarteritis Nodosa (PAN)

A
86
Q

Treatment of Takayasu arteritis

A
87
Q

Ustekinumab

A
88
Q

Vaccines and bDMARDs or tsDMARDs

A
89
Q

What are the classic causes of drug induced lupus (SLE)?

A
  • *Procainamide** and hydralazine the classics
  • genetic differences resulting in slower acetylation increase risk

Minocycline and TNF blockers more common now

90
Q

What are the relative 5yr mortality rates for the small and medium vessel vasculitides?

A
  • Microscopic polyangiitis (MPA) 28%
  • Polyarteritis nodosa (PAN) 25%
  • Eosinophilic Granulomatosis with Polyangiitis (EGPA)(Churg Strauss) 14%
  • Granulomatosis with Polyangiitis (GPA)(Wegener’s) 13%
  • Higher risk of relapse with anti-PR3 or cardiovascular involvement
  • Lower risk of relapse with renal involvement
91
Q

What characterises Granulomatosis with Polyangiitis (GPA)(Wegener’s)?

A

ANCA +ve vasculitis

  • 90% cANCA (PR3) +ve in generalised, 60% in limited

Presentation

  • ENT involvement in 95%: sinusitis, epistaxis, saddle-nose deformity, subglottic stenosis, otitis media, sensorineural hearing loss
  • pulmonary: haemorrhage, stridor, dyspnoea, wheezing, cavitating nodules
  • renal: glomerulonephritis picture (segmental necrotising pauci immune)
  • skin
  • opthalmologic in 50% (can get retroorbital granulomata), episcleritis

Management

  • limited (ENT only): prednisolone + azathioprine or methotrexate
  • severe: prednisolone + cyclophosphamide or rituximab (equivalent)
92
Q

What disease when it occur’s with Wegner’s causes worsened Wegner’s Phenotype

A

Alpha1 antitrypsin deficiency - especially Z genotype

93
Q

What is polyarteritis nodosa (PAN)?

A

Systemic necrotising medium vessel vasculitis

    • note frequently get overlap with microscopic polyangiitis (and then can get the GN/lung haemorrhage, etc)

Associated with Hep B in 1/3: higher mortality (34% vs 19%)
Also associated with hep C, HIV, hairy cell leukaemia

Presentation

  • organ ischaemia with infarction (bowel, kidney)
  • don’t get glomerulonephritis or lung haemorrhage
  • coronary arteries, neuropathy
  • orchitis, retinitis

Investigations

  • biopsy: focal, segmental pan-mural necrotising inflammation of medium-sized arteries with predeliction for bifurcations and branch points of muscular arteries
  • angiogram: stenoses, aneurysms, thrombosis
  • ANCA -ve (unless in overlap with MPA)

Management

  • high dose prednisolone + cyclophosphamide -> pred + azathiorpine maintenance
  • 80% 5yr survival
  • antivirals if hep B +ve
94
Q

What is Takayasu arteritis?

A

Chronic inflammatory granulomatous large vessel vasculitis

  • cause unclear
  • more common in Asians and South Americans

Affects aorta and its branches

    • Subclavian, carotid, vertebral, brachiocephalic, pulmonary arteries

Diagnostic criteria (3+/6 sens 90.5%, spec 97.8%)

    • young woman <40yrs
    • limb claudication
    • decreased brachial artery pulse
    • differential limb SBP >10mmHg
    • subclavian artery or aortic bruit
    • abnormal angiogram

Angiogram the gold standard

    • beading, stenosis, aneurysm

PET can be useful for diagnosis

    • doesn’t predict relapse or progression

Use CTA -> MRA for monitoring

    • to avoid having to regularly irradiate them

Management

  • 1st line high dose steroids +- steroid sparing
    • tociluzimab (IL-6 inhibitor) works
    • rituximab works
    • anti TNFa work
95
Q

Which connective tissue has the highest mortality

A

SCLERODERMA

96
Q

What characterises eosinophilic granulomatosis with polyangitis (EGPA)?

A

Asthma

    • later in life without a history of atopy

Sinus abnormalities

Peripheral eosinophilia

    • >10% one of the defining features
    • Present at Dx in <=80%, rapidly responds to therapy

Neuropathy in >75%

    • mononeuritis multiplex
    • cerebral haemorrhage or infarction important causes of death

Pulmonary infiltrates

    • PFTs often obstructive

Rash in 50%

    • purpura, nodules, urticarial rashes, livido

GI

    • ischaemic bowel, pancreatitis, cholecystitis portend poor prognosis

Cardiac

    • Involvement portends poor prognosis
    • Pericarditis, MI, ECG changes

Renal in 25%

    • proteinuria, GN, CRF/CKD, infarct

ANCAs in 50%

97
Q

What is the treatment for eosinophilic granulomatosis with polyangitis?

A

Steroids the mainstay

    • 50% of untreated die by 3 months
    • Treated have 6yr survival 70%
    • >90% achieve clinical remission, ~25% relapse

Cytotoxic agents may be used in presence of poor predictors

    • Cardiac, renal, GI
    • Cyclophosphamide: doesn’t increase survival but associated with reduced relapses and better response to treatment
    • Others MTx, azathioprine, IVIg, interferon a
98
Q

With what is reactive arthritis most commonly associated?

A

After 1% of nongonococcal urethritis and 2% of enteric infections

    • Y enterocolitica, shigella, to a lesser extent c jejuni and salmonella; may occur after c difficile
    • Only a minority have the classic findings: urethritis, conjunctivitis, uveitis, oral ulcers, rash

Most commonly in young men and linked to HLA-B27 locus

Most recover within 6 months

  • *Predictors of longer course**
  • male
  • post-chlamydial
  • extra articular features
  • HLA-B27 +ve
99
Q

What are the various lung manifestations and their frequencies in the connective tissue diseases (CTD)? WHy is it important to separate them from IPF?

A

Note it’s uncommon to see ILD in SLE

Important to differentiate due to prognostic factors

100
Q

What does an elevated AMA indicate?

A

Associated with _primary biliary cirrhosis (cholangitis), and multiple others
- 95% of those with PBC have AMA ab_

9 antigens have been identified, M1-M9
Can also be seen in Sjogren’s, systemic sclerosis, pulmonary TB, leprosy

101
Q

What are the toxicities associated with cyclophosphamide?

A

Bone marrow

  • cytopoenias: granulocytes then platelets then RBC
  • Nadir at 7-14 days, recovery by 21 days

Infection

  • Bacterial, opportunistic, viral
  • PCP prophylaxis indicated

Gonadal toxicity

  • Cumulative dose independent risk factor for toxicity
  • Should sperm/egg bank in those wanting fertility
  • Women: infertility and premature menopause
  • Men: decrease sperm count and irreversible azoospermia
  • Teratogenic

Malignancy

  • All haematological malignancies: lymphoma, MDS, leukaemia, myeloproliferative
  • Risk increases with cumulative dose
  • Skin and other cancers too

Bladder toxicity

  • Haemorrhagic cystitis and bladder cancer. Due to toxic metabolite acrolein
  • Cumulative dose related. Marked increase in risk of bladder cancer after haemorrhagic cystitis
  • Can give MESNA that neutralises the toxic metabolites to reduce haemorrhagic cystitis
  • Monitor urinalysis monthly on treatment and yearly off

SIADH

102
Q

What is the classic renal manifestation of Sjogren’s syndrome? How are they treated?

A
  • Tubulointerstitial nephritis with predominant lymphocytic infiltrate
  • Can also be associated with type 1 (distal) RTA, diabetes insipidus, moderate ARF (AKI)
  • Treatment
    • Glucocorticoids +- maintenance azathioprine/MMF to prevent relapse
103
Q

What type of renal manifestation is associated with IgG4 disease?

A
  • Form of AIN
  • Dense inflammatory infiltrate containing IgG4-expressing plasma cells
  • Also associated with
    • autoimmune pancreatitis
    • sclerosing cholangitis
    • retroperitoneal fibrosis
    • chronic sclerosing sailadenitis
104
Q

What is scleroderma (systemic sclerosis) renal crisis? What’s the prognosis?

A

Malignant hypertension, rapid decline in renal function, nephrotic proteinuria, haematuria, encephalopathy, pulmonary oedema, hypertensive retinopathy

  • occurs in 5-10% of those with systemic sclerosis
  • usually within the first 4yrs
  • highest risk in diffuse cutaneous or rapidly progressive, or recently commenced high dose steroid
  • linked to speckled ANA, anti-RNA polymerase, and absence of anti-centromere

Pathology

  • arcuate artery intimal and medial proliferation with luminal narrowing
  • ‘onion skinning’

Prognosis (untreated mortality ~100%)

  • 40-60% never recover renal function
  • captopril (only ACEi with data) improves outcomes but mortality at 5yrs still 30-40%
  • If renal function not back by 24 months it’s probably not coming back
105
Q

Which patients with antiphospholipid syndrome have the highest risk of thrombosis?

A

Venous more common than arterial thrombosis

    • 20-30% with APLS get low limb DVT (the most common location)
    • most common arterial is cerebrovasular

Lupus anticoagulant (LA) highest

    • OR ~10 for first VTE, ~6 for recurrence, ~10 for arterial

Anticardiolipin

    • NOT a risk for first VTE (OR 0.7), OR 1-6 for recurrence
  • - IS a risk for arterial thrombosis

Beta 2 glycoprotein

    • OR 2.4 for first VTE, no data for recurrence or arterial
    • and it’s the anti domain 1 IgG antibody that carries the real risk
  • *LA or triple positivity the big predictors of recurrent thrombosis**
  • recurrence rate 5-12% per year
106
Q

What proportion of those with SLE have renal involvement (lupus nephritis)? How does it present? Classes? Treatment?

A
  • *~50% at diagnosis,** ~60% at some point during disease
  • Most severe in African-American females

Markedly increased mortality in those with lupus nephritis compared to base population

Pathophysiology

    • Circulating immune complex deposition with complement activation and damage, leukocyte infiltration and cytokine release, activation of procoagulant factors
    • In situe complex formation from bidning of nuclear antigens
    • Antiphospholipid antibodies triggering thrombotic microangiopathy

Clinical

    • Proteinuria most common
    • Hypertension, haematuria, renal failure, active sediment can all be present
  • - dsDNA correlates best with renal disease
    • hypocomplementaemia is common (70-90%)in acute lupus nephritis and can herald a flare

Classification

  • Class I/II = limited to mesangium = excellent prognosis
  • Class III/IV = proliferative = poor prognosis = treatment
    • S = segmental, G = global, A = active, C = chronic
  • Class V = membranous and can be mixed with III/IV, in which case requires treatment
  • Class VI = Advanced Sclerosing = >=90% of glomeruli globally sclerosed

NIH biopsy scores (helps to decide re: immunosuppression)

Treatment (ONLY stage III/IV +/- V)

  • Induction with pred/methylprednisolone + MMF or cyclo for 2-6 months
  • Maintenance with MMF or azathioprine (MMF > aza for maint)

Microthrombosis due to antiphospholipid antibodies is a poor prognostic factor
- Even with anticoagulation

Transplant

  • ~20% reach ESRF requiring dialysis or transplant. Disease usually becomes quiescent, thought due to uraemia immunosuppression
  • Survival comparable to those transplanted for other reasons
107
Q

Which subtype of ANCA is more associated with granulomatosis with polyangiitis (Wegener’s)? What about microscopic polyangiitis?

A

cANCA -> PR3-ANCA for Wegener’s

pANCA -> MPO-ANCA for MP

108
Q

What is cryoglobulinaemia? What are the types? Who gets them? How do they present?

A

Cryoglobulins

  • - Ig and complement components that precipitate upon refrigeration of serum
    • Precipitation reverses on warming
  • - low C4 in 70-90%

Cryoglobulinaemia

    • systemic inflammatory syndrome generally with small-medium vessel vasculitis due to CG-containing immune complexes
    • types 2 and 3 referred to as mixed cryoglobulinaemia
    • in 2 and 3 IgM acts as rheumatoid factor that combines with Fc of usually IgG

Type I (isolated monoclonal Igs)

    • 10-15%
  • - Hyperviscocity secondary to high levels of monoclonal CG in lymphoproliferative disorders
    • Present with signs of hyperviscocity and/or thrombosis
    • Raynaud’s, digital ischaemia, livedo reticularis, purpura
    • Neurological symptoms or peripheral neuropathy
    • Predominantly affects the skin, kidney, and bone marrow

Type 2 (immunocomplexes of monoclonal IgM; usually with polyclonal IgG)

    • 50-60%
    • Strongly associated with HCV

Type 3 (immunocomplexes of polyclonal IgM; usually with polyclonal IgG)

    • 25-30%
    • Strongly associated with HCV and CTDs

Types 2 & 3

    • Skin, peripheral nervous system, and kidney
    • Arthralgias (>70%), fatigue, malaise common
    • Raynaud’s (~50%)
    • Sensory changes/weakness due to peripheral neuropathy
    • Palpable purpura in 90-95%
    • Meltzer’s triad: Purpura, arthralgias, and weakness seen in 25-30%
    • Causes 2% of biopsy proven GN -> membranoproliferative GN

Treatment

  • Underlying disease in secondary:
    • hep C associated antivirals + rituximab superior to antivirals alone. Rituximab superior to standard immunosuppression
    • ritux + pred superior to alkylating + pred in non-infectious secondary
    • PEx for severe or life threatening complications
109
Q

What are the two types of ANCA test?

A

Indirect immunoflourescence = more sensitive

  • *Enzyme Linked Immunosorbent Assay (ELISA) = more specific**
  • Identifies the antibody
  • C-ANCA by proteinase 3 (PR3)
  • P-ANCA by myeloperoxidase (MPO)
110
Q

What proportion are ANCA positive and what is the subtype in:

  • GPA, MPA, EGPA, Pauci-immune renal limited vasculitis, anti-GBM, drug induced ANCA-associated vasculitis
A
111
Q

What are the conditions other than vasculitis which can be associated with ANCA positivity?

A
  • • Autoimmune liver
    • o 90% of PSC
    • o 70% of chronic, active autoimmune hepatitis
  • • Rheumatoid arthritis
    • o Seen in 20%
  • • Pulmonary
    • o Seen in 90% of cystic fibrosis –> Correlated with worse disease
    • o See in 5% of ILD
  • • Gastrointestinal
    • ANCA associated with UC
      • pANCA +ve, ASCA –ve = 57% sens 97% spec
    • ASCA associated with Crohn’s
      • pANCA –ve, ASCA +ve = 50% sens 97% spec
112
Q

Does a rise in ANCA titres predict disease flare in vasculitis? Does conversion from positivity to negativity carry any meaning?

A

Rise in titres not predictive of a flare

Conversion to negativity associated with, but not proof of, remission

113
Q

What is anti-CCP? What is rheumatoid factor (RF)? Do they predict anything? Are they specific or sensitive?

A

Anti-CCP = IgG antibodies against proteins containing citrulline

  • Most specific antibody for RA (also predicts development of RA)
  • Sens 65%, spec 95%
  • mean onset prior to clinical disease 4.8yrs
  • Positivity predicts erosive disease and progressive joint damage
  • May be seen in SLE, Sjogren’s, Psoriatic Arthritis (PsA), tuberculosis

RF = IgM autoantibody against Fc portion of IgG, forming immune complexes

  • - Less specific than anti-CCP
    • Sens 60%, spec 88%; found in 15% of baseline population
    • Can act as a type 2 or 3 cryoglobulin
  • - Positivity associated with more severe joint disease and extra-articular manifestations
    • Seen commonly in: Sjogren’s, hep B/C, viral infection, PBC

Other RA associations

  • Age
  • CTD
    • Sjogren’s 70%
    • SLE 30%
    • PM 10%
  • Type 2 or 3 cryoglobulinaemia, as mentioned above
  • PBC
  • Chronic infections
  • Lymphoma/leukaemia
114
Q

What proportion of those with rheumatoid arthritis (RA) are ANA positive?

A

30-40%

115
Q

What two factors are associated with the large majority of atraumatic cases of avascular necrosis?

How do they present?

A

Glucocorticoids and ETOH abuse associated with >80% of atraumatic cases

  • Risk goes up with dose in both
  • Low risk in <15-20mg/day of prednisolone

~50% with sickle cell develop osteonecrosis by 35yrs

Presentation

  • Most late in the course
  • Most commonly anterolateral femoral head but can affect anywhere
  • Pain is most common: weightbearing/movement in most. Rest pain in 2/3, night pain in 1/3
116
Q

What are the imaging findings in avascular necrosis?

A

Xray

  • normal for months after process begins
  • crescent sign is pathognomonic, representing subchondral collapse
  • later stages show loss of sphericity and collapse
  • *Radionucleotide has very poor sensitivity**
  • *- doughnut sign =** increased turnover at the junction of dead and reactive bone
  • *MRI is ~100% sensitive**
  • surgery based on MRI alone can result in overtreatment
117
Q

What are giant cell arteritis (GCA) and polymyalgia rheumatica (PMR)? Go through their epidemiology and pathophysiology

A

GCA = medium/large vessel vasculitis predominantly affecting the thoracic aorta and its branches

    • most common vasculitis in those >50yrs
    • very rare for it to involve intracranial vessels

PMR = inflammatory disorder characterised by stiff/aching neck/shoulder/pelvic girdle

    • most common inflammatory rheumatic disease in the elderly

Epidemiology

  • Both affect >50yr old F:M 3:1
  • PMR 3-10x more common than GCA
  • 20% with PMR have GCA features
  • 50% with GCA have musculoskeletal PMR features
  • Both associated with HLA-DRB1*04 in Northern Europeans

Pathophysiology of GCA

  • hypothesised due to dendritic activation by toll like receptors (TLRs), resulting in chemokines recruiting CD4s and macrophages
  • TLRs are expressed variably and so would account for the ‘skip lesions’
  • transmural inflammation with TH1 and TH17 specifically are greatly increased in GCA affected tissues

Histology of GCA

    • Muscular arteries with well developed elastic laminae and vasa vasorum
    • Classic feature disruption of internal elastic lamina and intimal thickening, stays even with steroid treatment
  • - 50% have giant cells at intima/media junction
    • mainly CD4 and macrophage infiltration
    • VZV antigen present in GCA +ve much more frequently than controls (Neurology 2015)

Pathophysiology of PMR is poorly understood

  • Histology shows synovial infiltration by macrophages and T-cells
118
Q

What are the clinical and investigation findings in giant cell arteritis (GCA)?

A

Headache is temporal and resistant to analgesia
Visual loss usually due to anterior ischaemic optic neuritis with a chalky white disc. May be posterior ischaemic optic neuritis which doesn’t have white disc
Jaw claudication quite specific

CVA risk factors

    • age, IHD risk factors, lack of systemic manifestations, moderate inflammatory markers
    • any other iscahemic complication greatly increases risk

Clinical large vessel involvement typically after 3-4yrs

    • TAA 9%, AAA in 6.5%
  • *Investigations**
  • ESR >40 in 90%
  • *- IL-6 and BAFF correlate with ESR/CRP**
  • CRP a superior marker of disease activity
  • Temporal artery biopsy the gold standard, negative in 10-20%
  • Significantly lower yield as duration on steroids increases: 78% +ve in <2 weeks; 65% +ve in 2-4weeks; 40% +ve in >4weeks
  • *- U/S may show the halo sign: hypoechoic rim around the lumen**
  • *- PET shows severity and extent** but doesn’t look at the wall or lumen
119
Q

What are the clinical and investigation findings in polymyalgia rheumatica (PMR)? What do you need to differentiate it from?

A

Morning stiffness and aching are the hallmark

    • 100% in shoulders
    • 50-70% in neck/pelvis
    • bilateral, worse at night, worse with movement

40% have consitutional symptoms

  • *25%** have peripheral arthritis
  • asymmetric, non-erosive, self-limited, steroid responsive
  • *12% develop remitting seronegative symmetrical synovitis with pitting oedema**
  • distinct entitity that responds much more quickly to steroids than PMR and can be seen in many other conditions

Investigations

    • ESR >40 in 90%
    • 1/3 have subclinical large vessel arteritis on PET
    • 4% with PMR and no GCA features have positive temporal artery biopsy
    • MRI and U/S are 90% specific and sensitive when looking for: bilateral subacromial, subdeltoid, trochanteric, or cervical bursitis
    • peri rather than intraarticular inflammation

Can be hard to differentiate late onset rheumatoid arthritis or spondyloarthritis from PMR

  • +ve RF/CCP point to RA
  • Erosions = RA
  • Rapid and dramatic response to steroids point to PMR
  • Anterior uveitis, HLA-B27, sacroiliitis point to spondyloarthritis
120
Q

What are the diagnostic critera for giant cell arteritis (GCA) and polymyalgia rheumatica (PMR)?

How are they treated?

A

GCA (differentiation from other vasculitis rather than diagnostic tool): >=3 of the below is sens 93.5%, spec 91.2%

  • >50yrs onset
  • New headache
  • Temporal artery abnormality clinically
  • ESR >=50
  • Abnormal artery biopsy

GCA

  • - 40-60mg prednisolone daily, prevents ischaemic events which are usually irreversible. Pulse methylpred or higher dose oral if visual symptoms
  • - Aim to wean to 10-15mg by 3 months and then discontinue by 6-24 months
  • - Aspirin recommended based on retro data
    • MTX decreases relapse rate but not adverse events despite sparing steroid
    • Azathioprine can be used
    • TNFi doesn’t work
    • Tocilizumab works very well but not data yet on whether it alters ischaemic events

PMR

  • - 15-20mg prednisolone daily with slow wean over months
    • exquisitely rapid response
    • 50-70% improvement expected in 3-5 days, if not then question diagnosis

Look out for steroid complications

121
Q

Which subtype of giant cell arteritis (GCA) is associated with increased mortality?

A

GCA with thoracic aneurysm

122
Q

Go through the different picture on joint aspirations of various aetiologies.

What is the specificity and sensitivity of gram stain in septic arthritis?

A

Gram stain

    • Non-gonococcal sens 50-70%, spec high
    • Gonococcal sens <10%, spec high

Characteristics associated with septic effusion. Higher the WBC count more specific for a septic joint

    • WBC >25,000: sens 77%, spec 73%
    • WBC >50,000: sens 62%, spec 92%
    • WBC >100,000: sens 22%, spec 99%
    • PMN proportion >=0.9: sens 73%, spec 79%
    • LDH >250U/L: sens 100%, spec 51%
123
Q

With what are anti-Ro/SS-A and anti-La/SS-B associated?

A
  • *Primarily found in Sjogren’s**
  • Both in 30-60%
  • Ro only in 50-70% Sjogren’s
  • La rarely alone: seen in SLE or Sjogren’s

Ro only seen in 30% of SLE

  • Ro can cross the placenta and cause neonatal lupus

Others

  • Coeliac, polymyositis (PM), autoimmune liver disease
124
Q

What is psoriatic arthritis (PsA)? What is its epidemiology, pathology and pathogenesis?

A
  • *Inflammatory musculoskeletal disease with autoimmune and autoinflammatory features**
  • usually in individuals with psoriasis

Epidemiology

  • ~3% of white people have psoriasis
  • ~15% of those with psoriasis have psoriatic arthritis
  • duration and severity of psoriasis increase development of PsA
  • psoriasis directly associated with HLA-cw*0602
  • HLA-B27 associated with psoriatic spondylitis
  • first degree relatives have higher risk of psoriasis, PsA, and other spondyloarthritides
  • 30% with psoriasis have an affected first degree relative
  • 35-72% concordance in monozygotic twins for psoriasis, 10-30% for PsA

Pathogenesis

  • Diffuse infiltration with T and B-cells, macrophages, NK cells
  • Plasmacytoid dendritic cells play a key role in psoriasis, some evidence they participate in PsA
  • IL-17/23 are important, from TH17 T-cells
  • marked increase in osteoclastic precursors and upregulation of RANKL in synovium is consistent with extensive bone remodelling

Pathology

  • inflamed synovium like RA, but with less hyperplasia/cellularity and more tortuous vascular pattern
  • shows prominent enthesitis, unlike RA
125
Q

What are the clinical features of psoriatic arthritis (PsA)? The five general patterns?

A
  • *In 60-70% psoriasis precedes joints**
  • 15-20% appear within a year
  • 15-20% arthritis before psoriasis

Typically occurs in 4th-5th decade

90% with PsA have nail changes, 40% of psoriasis do

    • pitting, horizontal ridging, onycholysis, yellowing, dystrophic hyperkeratosis

Hallmarks

  • - dactylitis in >30%
    • enthesitis present in most but not always appreciable
    • finger shortening due to osteolysis is characteristic of PsA
    • back and neck pain/stiffness common

Patterns

  • Oligoarthritis
      • ~30% have asymmetric oligoarthritis
      • usually a knee or other large joint with a few small joints
  • Polyarthritis
      • 40% have symmetric polyarthritis
      • may be indistinguishable from RA in the joints involves
      • often has characteristic features to help differentiate
  • Axial
      • isolated in 5%
      • may be indistinguishable from idiopathic ankylosing spondylitis (AS)
      • PsA more neck and less thoracolumbar involvement
      • AS doesn’t get nail changes
  • Isolated DIPJ arthropathy with nail disease
      • in 5%
  • Arthritis mutilans in a small percentage
      • telescoping with gross destruction
  • Extraarticular
      • ocular in 7-33%: conjunctivitis or uveitis
      • uveitis in PsA more often bilateral, chronic, and/or posterior
      • aortic insufficiency in <4%, usually with longstanding disease
126
Q
A

Rheumatology (8 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions